Can Truehope lower health care costs?

Earlier this month, researchers at the University of Calgary and the Center for Integrative Psychiatry in The Netherlands published a study in BMJ Case Reports.

The researchers studied the results of 6 months of inpatient care for an 11-year-old boy who was being treated for Psychosis—NOS, OCD, borderline intellectual functioning, pediatric autoimmune neuropsychiatric disorders associated with Strep, generalized anxiety disorder, and social anxiety disorder. Then they studied the results of 6 months of outpatient care while he was taking EMPowerplus, our flagship product of 36 vitamins, minerals, amino acids, and antioxidants.

When the boy left inpatient care, his score on the Children’s Global Assessment Scale was 35, the same score he had when entering treatment six months earlier. His score remained unchanged despite receiving various medications (including quetiapine, risperidone, fluoxetine, fluvoxamine, and clonazepam); assessment or treatment from at least four child/adolescent psychiatrists; and consultation from a paediatric neurologist.

After starting EMPowerplus, the boy was medication-free after only 1 month. In addition, his psychosis symptoms resolved, his anxiety-related symptoms abated, and all diagnoses were fully remitted by 14 months. When he was discharged from outpatient care, his CGAS had doubled to 70, and he has not required further mental health treatment for over 3 years.

What is also interesting  however, is that when researchers compared the cost of his inpatient care with the cost of his outpatient care, they a vast difference in the costs of delivery between the two. Six months of inpatient care cost nearly $160,000, while six months of outpatient care as an EMPowerplus participant cost nearly $3000. The conventional treatment route cost about 55 times that of the second route and saw virtually no improvement in symptoms.